Last reviewed · How we verify
Accelerated 30 minutes-infusion
This drug works by inhibiting the PD-1 receptor, which is involved in immune suppression.
At a glance
| Generic name | Accelerated 30 minutes-infusion |
|---|---|
| Also known as | Infliximab (Remicade, Centocor, Malvern, Philadelphia, PA) |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
By blocking PD-1, the drug allows the immune system to recognize and attack cancer cells more effectively. This leads to an increase in the body's immune response against cancer. The drug has been shown to be effective in treating various types of cancer.
Approved indications
Common side effects
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction (PHASE3)
- Reversing Glucose and Lipid-mediated Vascular Dysfunction (EARLY_PHASE1)
- Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction (PHASE4)
- Accelerated Recovery Following Opioid-free Anaesthesia in Supratentorial Craniotomy (NA)
- Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC (EARLY_PHASE1)
- Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer (PHASE1, PHASE2)
- A Study of APG-1252 in Patients With SCLC or Other Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Accelerated 30 minutes-infusion CI brief — competitive landscape report
- Accelerated 30 minutes-infusion updates RSS · CI watch RSS
- Asan Medical Center portfolio CI